Citadel Advisors’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
Other funds holding CSBR
BMC
NMC
TAM
MBAM
Citadel Advisors's CSBR Position: Q4 2025 in Review
Citadel Advisors sold out of Champions Oncology (CSBR) in Q4 2025, closing a stake of 16,326 shares — an estimated $106K sold.
Citadel Advisors first reported a position in CSBR in Q3 2016 and held it in 14 quarters. The position peaked at $280K in Q3 2022. 27 funds tracked by Wall St. Rank hold CSBR as of Q4 2025.
- Citadel Advisors reported no remaining Champions Oncology position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 16,326 Champions Oncology shares in Q4 2025, an estimated $106K.
- Citadel Advisors first reported a position in Champions Oncology in Q3 2016 and held it in 14 quarters.
- Citadel Advisors's Champions Oncology position peaked at $280K in Q3 2022.
- 27 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.